Why “Good” Is Expensive: The Cost of Falling Below 4 Stars in Medicare Advantage
A 3.5-Star Medicare Advantage rating can be far more expensive than it looks. As an example, in 2026, approximately 40% of Medicare Advantage prescription drug contracts earned four Stars or higher, meaning roughly six in 10 fell below that threshold. These ratings will affect 2027 Medicare Advantage Quality Bonus Payments, making today’s quality performance a […] The post Why “Good” Is Expensive: The Cost of Falling Below 4 Stars in Medicare Advantage appeared first on Becker's Payer Issues...
View related coverage on the timeline →
Useful signal?
Sign in with GitHub below to react 👍 / 👎, or comment if a category looks wrong — your reactions help curate this feed. How feedback works
Draft Insight Angle
Auto-generated draft — review and edit before any external use.
Policy / Regulatory Changes signal via Becker's Payer Issues: "Why “Good” Is Expensive: The Cost of Falling Below 4 Stars in Medicare Advantage".
Analytic angles
- Compare against the current CMS rate/bid-cycle documents.
- Single-source so far — corroborate against a second outlet.
Draft paragraph
[DRAFT — verify before any external use] Becker's Payer Issues reports on policy / regulatory changes: A 3.5-Star Medicare Advantage rating can be far more expensive than it looks. As an example, in 2026, approximately 40% of Medicare Advantage prescription drug contracts earned four Stars or higher, meaning roughly six i…
Note: This is an early signal based on public reporting. Confirm against primary sources before drawing conclusions. Market dynamics may shift as additional information emerges.